Search

Your search keyword '"Abad, David"' showing total 1,489 results

Search Constraints

Start Over You searched for: Author "Abad, David" Remove constraint Author: "Abad, David"
1,489 results on '"Abad, David"'

Search Results

1. Electric charge quantization in 331 Models with exotic charges

2. Heavy long-lived fractionally charged leptons in novel $3-3-1$ model

3. Fixing the number of non-sequential generations within the $SU(2)_{L}\otimes U(1)_{Y}$ gauge group

4. Response of Horticultural Soil Microbiota to Different Fertilization Practices.

5. How Large Is Infinity?

8. The Magnetic Field in the Axis of an Elliptic Loop Current

9. Considerations on diagnosis and surveillance measures of PTEN hamartoma tumor syndrome: clinical and genetic study in a series of Spanish patients

10. Two-center experience comparing the use of the FLOT4 and CROSS schemes for patients with gastric, esophageal, and gastroesophageal junction adenocarcinoma.

12. Analizando el protocolo SPIKES desde la perspectiva del paciente oncológico

13. Non-Standard Errors

14. Nonstandard Errors

15. Non-Standard Errors

24. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

25. Z' boson decay in the SU(3)L \otimes U(1)N electroweak model with heavy leptons

33. Co-Existence of blaNDM-1, blaOXA-23, blaOXA-64, blaPER-7 and blaADC-57 in a Clinical Isolate of Acinetobacter baumannii from Alexandria, Egypt

35. News and updates in the treatment of localized stage triple-negative breast cancer

38. Different Diets Based on Yellow Mealworm (Tenebrio molitor)—Part B: Modification of the Intestinal Inflammatory Response and the Microbiota Composition of Rainbow Trout (Oncorhynchus mykiss)

39. Supplementary Table 2 from Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial

40. Supplementary Table 3 from Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial

41. Supplementary Table 4 from Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial

42. Supplementary Figure 2 from Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial

43. Supplementary Figure 3 from Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial

44. Supplementary Figure 1 from Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial

45. Reacción del mercado a las entradas y salidas del índice IBEX-35 (2000-2022)

46. Evaluación continua en el área de contabilidad/finanzas

47. Market-wide illiquidity and the distribution of non-parametric stochastic discount factors

48. Different Diets Based on Yellow Mealworm (Tenebrio molitor)—Part B: Modification of the Intestinal Inflammatory Response and the Microbiota Composition of Rainbow Trout (Oncorhynchus mykiss)

49. The Energy of Two Inverted Oppositely Moving Wave Pulses: A Graphical Approach.

50. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

Catalog

Books, media, physical & digital resources